Legend Biotech is preparing a leadership transition, with plans to appoint Ingrid Zhang as its new chief executive officer. Zhang, currently an executive at Novartis, is expected to step into the role as the company continues its focus on cancer-treatment development. The move signals a strategic shift for the biotech firm as it navigates a cooling market environment where defensive health plays have outperformed many growth-oriented alternatives.